CD-1 mice were vaccinated intragastrically or intramuscularly with one or two doses of 200,g of heat-killed Salmonella enteritidis 5694. Control mice were vaccinated with sublethal doses of living S. enteritidis Se795. The mice were challenged intragastrically with approximately 106 S. enteritidis 5694 SMR 7 to 14 days later, and the growth of the challenge population in the liver, spleen, mesenteric lymph nodes, lungs, and intestine was measured quantitatively. Mice receiving two doses of heat-killed vaccine by mouth were able to delay the systemic emergence of a gastrically introduced salmonella infection by 1 to 2 days. The corresponding liver and spleen populations were slightly lower than those seen in the normal controls. On the other hand, mice receiving the living, attenuated vaccine (either intravenously or intragastrically) developed an effective anti-salmonella immunity against subsequent reinfection.
Attempts to infect mice with Pasteurella multocida and Salmonella enteritidis intragastrically suggested that bacteria introduced into the stomach with a gavage needle did not result in pulmonary involvement nor was there systemic infection via minor abrasions of the esophagus or gastric mucosa. The significance of these findings is discussed with regard to their relevance for the oral mouse protection test used for the assessment of typhoid vaccines.
Vaccinating regimens currently used in the prophylaxis of typhoid fever largely stem from the pioneering studies of Wright about the turn of the century (19) . In addition to the use of killed, parenterally injected Salmonella typhi suspensions, however, a number of attempts have been made (both accidentally and intentionally) to induce immunity with living, oral vaccines; the development of severe clinical typhoid fever in some of the vaccines forced the abandonment of these early human experiments (16, 39) . Recently, protection studies have been carried out in chimpanzees (12, 20, 23) , in human volunteers (17, 18) , and in mice (7, 27, 34) which indicate that some protection may develop when inactivated vaccines are presented to the host by mouth, although the immunity developed in a recent human field trial appeared to be minimal, even with massive vaccine doses (3) . However, antityphoid immunity is probably never absolute, even under ideal conditions, except perhaps in the case of the permanent typhoid carrier (8) . The experimental finding that C57B1 mice vaccinated with a living attenuated vaccine can still be superinfected (9) is consistent with the well-known fact that second attacks of typhoid fever can occur naturally within months of the primary infection (17, 31) . Thus, even during convalescence, resistance to reinfection may decline so rapidly that second (although usually milder) attacks of the disease can occur if the infectious dose is large enough (9) or the virulence of the reinfecting strain is very high (31) .
Some mouse protection studies with orally vaccinated animals have suggested that killed salmonellae can increase the level of host resistance to enteric infection (33, 35) . Oral inoculation of killed vaccines (26, 34) or the direct injection of antigenic material into Peyer's patches (11) will induce specific immunoglobulin production, with rising immunoglobulin A titers in both the systemic circulation and in the intestinal secretions (40) . Humoral responses to a wide variety of nonreplicating antigens are readily observed in orally vaccinated animals (15) , although the precise nature of the immunoglobulin response may be quantitatively different from that seen after parenteral injection (28, 29) . Interest in the role of secretory antibodies in the expression of resistance to enteric infection (40) has thus restimulated attempts to induce acquired resistance by means of oral vaccines. As a result, protection or local antibody responses within the intestinal contents, or both, have recently been reported against cholera (37) , dysentery (18) , and enteric fever (17, 22) .
Mice infected with sublethal doses of virulent S. enteritidis develop progressive systemic infections which can be monitored by means of serial viable counts carried out on saline homogenates of the intestine, draining lymph nodes, liver, spleen, and blood (7) . Under these conditions, "protection" can be detected either by the absence of systemic infection or as a significant change in the bacterial growth pattern in vivo (7, 8 (9) . The inoculum was introduced into the stomach with a bent, gauge 19, stainless-steel 2-inch feeding needle with a smooth, 3-mm ball on the end (Popper and Sons, New York, N.Y.). The mouse was held in a vertical position, and the needle was carefully introduced into the esophagus and down into the stomach. Accidental discharge of part of the inoculum into the mouth or esophagus resulted in the regurgitation of part of the inoculum; an excess of fluid appeared in the animal's mouth and, occasionally, bubbles were seen at the nose. All such animals were discarded from the experiment.
Intravenous challenge. Mice were injected with 101 live S. enteritidis 5694 SMR suspended in 0.1 ml of saline via a tail vein. The viability of the challenge inocula was checked by plating suitable saline dilutions onto Tryptose soy agar (TSA) immediately after completion of the infection process.
Bacterial enumeration technique. The intestine, liver, spleen, lung, and mesenteric lymph nodes from five randomly selected mice were removed aseptically and homogenized separately in saline as described elsewhere (7). The gut counts were carried out on XL agar (BBL, Cockeysville, Md.) on which the S. enteritidis colonies produced a black center. Bacterial counts of the other organ homogenates were made on TSA. When in doubt, colonies were checked by slide Virulence tests. Virulence tests were carried out as described earlier (32) , and the LD5o was determined by the method of Reed and Muench (36) .
RESULTS
Heat-killed intragastric vaccine. Mice vaccinated with a single dose of 200 ,ug of heat-killed S. enteritidis developed a systemic S. enteritidis infection very similar to that seen in the normal controls (Fig. 1) . Mice receiving two doses of vaccine 1 or 2 weeks apart showed some protection, judging from the slower systemic emergence of the infection and a 10-fold reduction in the maximum bacterial population developing in the liver and spleen (Fig. 1) . The difference between the liver and spleen counts in the doubly vaccinated mice and that seen in the corresponding control animals was small, although it was significant at the 5% level. Oral vaccination of CD-1 mice with killed suspensions of S. enteritidis was never able to prevent the development of clinical disease in the challenged mice.
When intragastrically vaccinated mice were challenged intravenously, the growth rate for the S. enteritidis 5694 in vivo was again reduced slightly compared with that for the controls (Fig.  2) , but all of the vaccinated mice were obviously ill by day 5. It is doubtful if the observed differences in the growth rates in vivo had any practical significance so far as typhoid prophylaxis is concerned. All (6, 10) and have been omitted; those for the intragastrically challenged mice are shown in Fig. 3 . The host response to the killed systemic vaccine delayed the emergence of the challenge infection from the intestine for a day or so; but subsequently the in vivo growth curves for both vaccinated and control mice were very similar (Fig. 3) .
Live S. enteritidis vaccine. The killed vaccine merely slowed the development of the salmonella infection but had marginal effects on the ultimate size of the in vivo population (both effects could have some protective advantage for the host under natural conditions, however). It was decided to compare this level of protection with that routinely seen in convalescent mice. Normal mice were vaccinated intragastrically or intravenously with a single, sublethal dose of S. enteritidis Se795 and then were challenged intragastrically with S. enteritidis 5694 SMR some 10 to 20 days later. The resulting growth curves for the intragastrically vaccinated mice are shown in Fig. 4 and for the intravenously vaccinated mice are shown in Fig. 5 (8) . The mere persistence of viable salmonellae in the gut contents may not immunize the host against a subsequent superinfection (7, 9).
Aerogenic infection with S. enteritidis. Although S. enteritidis is an intestinal parasite, it can also invade the tissues via the lung (13) . Mice infected aerogenically with as few as 102 or as many as 106 viable S. enteritidis develop a progressive pulmonary infection which usually continued for about 6 days and then slowly declined. Ultimately, this infection spread to the liver and spleen but bacterial growth in these organs normally ceased before reaching lethal proportions. The aerogenically induced infection always seemed to develop more slowly than was the case for the parenterally infected animal. As a result, it was not possible to accurately estimate the aerogenic LD50 for S. enteritidis (Table 1) , largely because of technical difficulties associated with the introduction of very large numbers of salmonellae into the normal lung.
When mice were infected orally with S. enteritidis by placing 107 viable organisms in the mouth (in a volume of 0.05 ml of saline) and then allowing the animals to swallow the inoculum naturally, significant numbers of salmonellae could be isolated from the lungs of some of the animals. The variation in the lung counts after 1 hr was understandably high and, in fact, the lungs of three out of five test animals in one experiment did not contain detectable numbers of S. enteritidis; however, the other two animals had lung counts of 1,800 and 6,700 viable S. enteritidis, respectively. When the same inoculum (in 0.2 ml of saline) was carefully introduced into the stomach with a gavage needle, none of the 10 Technical problems made it difficult to determine the precise fate of the pasteurellae within the gut, but it was assumed that the organisms were rapidly inactivated in the stomach or were eliminated In another experiment, small areas of the flank skin of normal CD-1 mice were shaved (30) , and a drop of P. multocida or S. enteritidis 5694 broth culture was rubbed onto the bare skin with a throat swab. Five of the 10 pasteurella-treated mice died within 36 hr; however, none of the survivors had culturable pasteurella in the liver or spleen at 72 hr. All of the mice swabbed with the S. enteritidis 5694 developed salmonellosis, with counts of 6.3 i 1.2 X 104 viable organisms in the spleen and 6.0 4 1.4 X 104 viable organisms in the liver on day 8. When the experiment was repeated with the more attenuated Se795 strain, no organisms could be detected systemically 5 or 8 days later. Infection through such minor skin abrasions apparently depends upon the virulence of the salmonella in question.
DISCUSSION
Although vaccination against enteric disease has been in use for more than 70 years, few immunologists have given serious consideration to the oral route of inoculation as a practical method for the prophylaxis of typhoid fever (16) . Many qualitative (and frequently inadequately controlled) oral-protection studies were reported in the early literature but few definitive conclusions can be drawn about most of them. Even in recent years, there has been an ongoing controversy over the practical effectiveness of many of these inactivated vaccines (8, 25) . It is only relatively recently that carefully and adequately controlled field trials have established statistical proof of the protective value of parenterally introduced killed typhoid vaccines for man (25) . Very little information of an analogous nature exists for killed, oral salmonella vaccines (3, 16) . The extensive studies of Raettig and his colleagues (27, 28, 33, 34) suggest that inactivated oral vaccines have some protective value for mice; however, experimental protection studies in chimpanzees (20, 23) and in human volunteers (17) indicate that the actual level of protection afforded against a controlled S. typhi challenge is, at best, marginal, and in practice many such immunogens appear to be valueless (3) . The results from the present study indicate that mice receiving two doses of the killed, oral vaccine showed a slight, though statistically significant (P < 0.05), reduction in the size of the liver and spleen populations by day 6 to 8 compared with the normal controls (Fig. 1) . Such "protection" could not be assessed in terms of increased survival rates because all of the animals received sublethal challenge doses of S. enteritidis. It seems reasonable to suppose that the oral vaccine had induced some type of local response on the part of the host and that this was responsible, in some manner, for the slower emergence of the systemic infection. However, such an immunizing regimen was never able to prevent the salmonellae from crossing the intestinal mucosa and ultimately infecting the liver and spleen. Furthermore, the rate of growth by the liver and spleen populations in the vaccinated and control mice was not apparently affected in mice pretreated with the killed vaccine, whether given intramuscularly (Fig. 3) or intragastrically (Fig.  1) . In fact, the growth pattern for the salmonella challenge in both groups of vaccinated mice was characteristic of the humorally mediated response (2, 8) rather than of that seen in convalescent animals (cf. Fig. 1 and 4) .
The intragastric infection route overcomes much of the criticism levelled against the intraperitoneal mouse protection test (7, 8) . In particular, the oral challenge method results in a better dose response with increasing numbers of virulent salmonellae than is the case for the intraperitoneal route. In the absence of specific opsonin, the extracellular bacteria in the peritoneal cavity multiply extensively, so that an initially small inoculum can increase many thousand-fold in a few hours, making it almost impossible to infect the animals with accurately graded challenge inocula. In the case of the orally infected mouse, the challenge infection is in an intracellular environment by the time it reaches the lamina propria (38) , and there appears to be little tendency on the part of the salmonellae to multiply freely within the gut contents (7) . In consequence, the number of living bacteria reaching the liver and spleen seems to be roughly proportional to the size of the initial infecting population (9) . Nevertheless, the size of the oral challenge dose required to kill most of the normal control mice (1, 24) makes this model equally unrealistic in terms of human disease (8) . Quantitation of the in vivo behavior of sublethal doses of S. enteritidis in vaccinated and control mice (9) permits a more realistic evaluation of the relative immunogenicity of killed salmonella vaccines (8) . However, the test system is still subject to several potential artifacts. One of the most serious of these would be the systemic entry of viable salmonellae through the lungs (13), the tonsils (14) , or by direct entry into the blood stream via minor mucosal abrasions caused by the introduction of the gavage needle into the esophagus (21) . Such errors seem more remote in view of the inability to infect mice with P. multocida by the oral route. Normal CD-1 mice are highly susceptible to aerogenic challenge with P. multocida. 
